Sight Sciences (SGHT)

Executive Summary

Sight Sciences (Nasdaq: SGHT) is a commercial-stage medical technology company focused on minimally invasive interventions for prevalent eye diseases, specifically glaucoma and dry eye disease. The company's two flagship platforms—OMNI® (for glaucoma) and TearCare® (for dry eye)—target the underlying causes of these conditions, offering surgeons intuitive, cost-effective alternatives to traditional therapies. With a growing installed base and strong clinical evidence, Sight Sciences is positioned to capture share in the large and underserved ophthalmic device markets. The company went public in 2021 and has since focused on commercial expansion, reimbursement coverage, and building clinical data to support adoption. Sight Sciences continues to invest in clinical trials and product development to expand its indications and strengthen its competitive moat. While the company faces a mixed reimbursement landscape and competition from established players, its innovative platforms have demonstrated strong clinical utility and patient outcomes. Recent pipeline activities include a terminated trial for Latanoprost plus adjunctive glaucoma medication and a completed dry eye study. Looking ahead, the company's growth will depend on execution of its commercial strategy, new product launches, and potential label expansions. The conviction score reflects the company's solid revenue trajectory and clear market need, tempered by competitive and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of OMNI for combined cataract and glaucoma procedure label expansion70% success
• Q1 2027Publication of pivotal trial results for TearCare in moderate-to-severe dry eye60% success
• H1 2027Announcement of international distribution partnership for OMNI platform50% success